产品
编 号：F743958
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1312299-39-0
产品详情
生物活性：
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
体内研究：
Concizumab (i.v./s.c.) 阻断 TFPI 与食蟹猴中 FXa 活性位点的相互作用。Animal Model:Cynomolgus monkeys (target mediated drug disposition (TMDD) model).
Dosage:20mg/kg or 200 mg/kg
Administration:Intravenous injection/subcutaneous injection
Result:Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.
体外研究：
Concizumab 以浓度依赖性方式增加凝血酶峰值。
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
体内研究：
Concizumab (i.v./s.c.) 阻断 TFPI 与食蟹猴中 FXa 活性位点的相互作用。Animal Model:Cynomolgus monkeys (target mediated drug disposition (TMDD) model).
Dosage:20mg/kg or 200 mg/kg
Administration:Intravenous injection/subcutaneous injection
Result:Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.
体外研究：
Concizumab 以浓度依赖性方式增加凝血酶峰值。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备